CP and COVID-19: Both RCTs were terminated prematurely due to the concerns over the potential benefit of CP in the study population with high neutralizing antibody titers (≥1:160) at baseline [125] and the lack of patients with COVID-19 to reach the planned recruitment target of 200 patients [294], resulting in an underpowered study sample size.